



ATALANTE



- Randomized phase III trial comparing atezolizumab versus placebo in patients with 1st or 2nd late relapse (TF1p > 6 months) of OC treated with carboplatin combination + bevacizumab
- Sponsor ARCAGY-GINECO
- PI: JE Kurtz . Scientific coordinator/ E Pujade-Lauraine






A Phase 2 Randomized Umbrella Trial in Recurrent Ovarian Cancer

Sponsor: NSGO

Lead Groups: different groups for different cohorts

**Trial-Specific/Satellite Meeting
Wednesday 4:30pm
Room 17F**



Cediranib and Olaparib versus Platinum based chemotherapy in Sensitive Recurrent Ovarian Cancer

AGO-OVAR 2.28